Hear from a promising drug company that was founded by medical researchers from three Milwaukee-area universities at the Thursday, May 9 luncheon meeting of the Tech Council Innovation Network in Wauwatosa.
Formed in 2018, Estrigenix Therapeutics has patented a small molecule drug that acts like estrogen to reverse the adverse symptoms associated with menopause, such as hot flashes. It also has potential to counter long-term onset dementia and memory decline in post-menopausal women between 55 and 65 years old.
Panelists are Estrigenix Therapeutics founders Dr. Karyn Frick of the UW-Milwaukee and Dr. Daniel Sem of Concordia University Wisconsin. Along with a professor from Marquette University, the trio brings interlocking expertise in dementia and menopause, medicinal chemistry and drug development.
The company is a finalist in the 2019 Wisconsin Governor’s Business Plan Contest, which culminates June 4-5 at the Wisconsin Entrepreneurs’ Conference at Milwaukee’s Venue42.
The May 9 event will take place at UW-Milwaukee’s Innovation Accelerator, 1225 Discovery Parkway. Registration, networking and hors d’oeuvres start at 11:30 a.m. and the presentation at 12:30 p.m. The cost is $10 for students and returning veterans, $25 for individual members, $35 for non-members and included for Tech Council corporate members. Click here to register.
“Not only is the Estrigenix drug a promising candidate to help women everywhere, but the story of how three universities have collaborated on research and company formation is instructive for other academic researchers in many fields,” said Tom Still, president of the Wisconsin Technology Council.
The Tech Council is the independent, non-profit science and technology adviser to the governor and Legislature, with events, publications and outreach that build Wisconsin’s tech-based economy. To join, go to www.wisconsintechnologycouncil.com or call 608-442-7557.